ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Transarterial Chemoembolization (TACE) Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-18Y13983
Home | Market Reports | Health| Health Conditions| Cancer
Global Transarterial Chemoembolization TACE Market Research Report 2023
BUY CHAPTERS

Global Transarterial Chemoembolization (TACE) Market Research Report 2025

Code: QYRE-Auto-18Y13983
Report
May 2025
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis
Pfizer Inc
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer
Merck& Co. Inc
SingHealth

Transarterial Chemoembolization (TACE) Market Size

The global market for Transarterial Chemoembolization (TACE) was valued at US$ 12670 million in the year 2024 and is projected to reach a revised size of US$ 21890 million by 2031, growing at a CAGR of 8.3% during the forecast period.

Transarterial Chemoembolization (TACE) Market

Transarterial Chemoembolization (TACE) Market

Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
The global Transarterial Chemoembolization (TACE) market refers to the market for a minimally invasive procedure used in the treatment of liver cancer. TACE is a locoregional therapy that combines chemotherapy and embolization to deliver anticancer drugs directly to the tumor site while blocking the blood supply to the tumor.
Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide. TACE has emerged as a commonly used treatment option for patients with intermediate-stage HCC or those who are not eligible for surgical resection or liver transplantation.
The TACE procedure involves the insertion of a catheter into the hepatic artery, the main blood supply to the liver. Through the catheter, a drug-eluting bead or emulsion containing chemotherapeutic agents is infused directly into the tumor, followed by the injection of embolic agents to occlude the blood vessels feeding the tumor. This dual action targets the tumor cells and restricts their blood supply, thereby delaying tumor growth and potentially shrinking the tumor.
Some key factors driving the global TACE market include:
Increasing incidence of liver cancer: The rising prevalence of liver cancer, particularly HCC, has led to an increased demand for effective treatment options. TACE offers a targeted approach for patients with intermediate-stage HCC, who represent a significant portion of liver cancer cases.
Limited surgical options: Liver resection and transplantation remain the most effective treatment options for early-stage HCC. However, many patients are not eligible for surgery due to the size and location of the tumor, underlying liver disease, or other patient factors. TACE provides a non-surgical alternative for these patients.
Advancements in imaging and catheterization techniques: The advancements in imaging technologies, such as computed tomography (CT) and fluoroscopy, have improved the precision and safety of TACE procedures. Additionally, the development of better catheterization techniques and embolic agents has enhanced the effectiveness and outcomes of TACE.
Multidisciplinary approach to cancer treatment: TACE is often used as part of a multidisciplinary approach to treating liver cancer. It may be combined with other interventions, such as radiofrequency ablation, sorafenib therapy, or immunotherapy, to achieve better treatment outcomes.
The global TACE market includes various players, including medical device manufacturers, pharmaceutical companies, and healthcare providers offering TACE equipment, drugs, and related services. Additionally, research and development activities are continually focused on improving the effectiveness and safety of TACE procedures and developing innovative embolic agents and drug formulations.
This report aims to provide a comprehensive presentation of the global market for Transarterial Chemoembolization (TACE), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transarterial Chemoembolization (TACE).
The Transarterial Chemoembolization (TACE) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Transarterial Chemoembolization (TACE) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transarterial Chemoembolization (TACE) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Transarterial Chemoembolization (TACE) Market Report

Report Metric Details
Report Name Transarterial Chemoembolization (TACE) Market
Accounted market size in year US$ 12670 million
Forecasted market size in 2031 US$ 21890 million
CAGR 8.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG, Pfizer Inc., Spectrum Pharmaceutical, Roche Holding AG, Celgene, Bayer AG, Merck & Co., Inc., SingHealth
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Transarterial Chemoembolization (TACE) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Transarterial Chemoembolization (TACE) Market growing?

Ans: The Transarterial Chemoembolization (TACE) Market witnessing a CAGR of 8.3% during the forecast period 2025-2031.

What is the Transarterial Chemoembolization (TACE) Market size in 2031?

Ans: The Transarterial Chemoembolization (TACE) Market size in 2031 will be US$ 21890 million.

Who are the main players in the Transarterial Chemoembolization (TACE) Market report?

Ans: The main players in the Transarterial Chemoembolization (TACE) Market are Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG, Pfizer Inc., Spectrum Pharmaceutical, Roche Holding AG, Celgene, Bayer AG, Merck & Co., Inc., SingHealth

What are the Application segmentation covered in the Transarterial Chemoembolization (TACE) Market report?

Ans: The Applications covered in the Transarterial Chemoembolization (TACE) Market report are Hospitals, Clinics, Cancer Research Centers

What are the Type segmentation covered in the Transarterial Chemoembolization (TACE) Market report?

Ans: The Types covered in the Transarterial Chemoembolization (TACE) Market report are Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-eluting Particles, Others

Recommended Reports

Interventional Devices

Embolization Solutions

Oncology & Ablation

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transarterial Chemoembolization (TACE) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapeutic Agents
1.2.3 Radio Therapeutic Agents
1.2.4 Drug-eluting Particles
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transarterial Chemoembolization (TACE) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Research Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transarterial Chemoembolization (TACE) Market Perspective (2020-2031)
2.2 Global Transarterial Chemoembolization (TACE) Growth Trends by Region
2.2.1 Global Transarterial Chemoembolization (TACE) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Transarterial Chemoembolization (TACE) Historic Market Size by Region (2020-2025)
2.2.3 Transarterial Chemoembolization (TACE) Forecasted Market Size by Region (2026-2031)
2.3 Transarterial Chemoembolization (TACE) Market Dynamics
2.3.1 Transarterial Chemoembolization (TACE) Industry Trends
2.3.2 Transarterial Chemoembolization (TACE) Market Drivers
2.3.3 Transarterial Chemoembolization (TACE) Market Challenges
2.3.4 Transarterial Chemoembolization (TACE) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transarterial Chemoembolization (TACE) Players by Revenue
3.1.1 Global Top Transarterial Chemoembolization (TACE) Players by Revenue (2020-2025)
3.1.2 Global Transarterial Chemoembolization (TACE) Revenue Market Share by Players (2020-2025)
3.2 Global Transarterial Chemoembolization (TACE) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Transarterial Chemoembolization (TACE) Revenue
3.4 Global Transarterial Chemoembolization (TACE) Market Concentration Ratio
3.4.1 Global Transarterial Chemoembolization (TACE) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transarterial Chemoembolization (TACE) Revenue in 2024
3.5 Global Key Players of Transarterial Chemoembolization (TACE) Head office and Area Served
3.6 Global Key Players of Transarterial Chemoembolization (TACE), Product and Application
3.7 Global Key Players of Transarterial Chemoembolization (TACE), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Transarterial Chemoembolization (TACE) Breakdown Data by Type
4.1 Global Transarterial Chemoembolization (TACE) Historic Market Size by Type (2020-2025)
4.2 Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Type (2026-2031)
5 Transarterial Chemoembolization (TACE) Breakdown Data by Application
5.1 Global Transarterial Chemoembolization (TACE) Historic Market Size by Application (2020-2025)
5.2 Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Transarterial Chemoembolization (TACE) Market Size (2020-2031)
6.2 North America Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025)
6.4 North America Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transarterial Chemoembolization (TACE) Market Size (2020-2031)
7.2 Europe Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025)
7.4 Europe Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size (2020-2031)
8.2 Asia-Pacific Transarterial Chemoembolization (TACE) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region (2020-2025)
8.4 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transarterial Chemoembolization (TACE) Market Size (2020-2031)
9.2 Latin America Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025)
9.4 Latin America Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size (2020-2031)
10.2 Middle East & Africa Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025)
10.4 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Questex
11.1.1 Questex Company Details
11.1.2 Questex Business Overview
11.1.3 Questex Transarterial Chemoembolization (TACE) Introduction
11.1.4 Questex Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.1.5 Questex Recent Development
11.2 Siemens Healthcare GmbH
11.2.1 Siemens Healthcare GmbH Company Details
11.2.2 Siemens Healthcare GmbH Business Overview
11.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Introduction
11.2.4 Siemens Healthcare GmbH Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.2.5 Siemens Healthcare GmbH Recent Development
11.3 Bellicum Pharmaceuticals Inc.
11.3.1 Bellicum Pharmaceuticals Inc. Company Details
11.3.2 Bellicum Pharmaceuticals Inc. Business Overview
11.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Introduction
11.3.4 Bellicum Pharmaceuticals Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.3.5 Bellicum Pharmaceuticals Inc. Recent Development
11.4 Boston Scientific
11.4.1 Boston Scientific Company Details
11.4.2 Boston Scientific Business Overview
11.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Introduction
11.4.4 Boston Scientific Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.4.5 Boston Scientific Recent Development
11.5 Cook Group
11.5.1 Cook Group Company Details
11.5.2 Cook Group Business Overview
11.5.3 Cook Group Transarterial Chemoembolization (TACE) Introduction
11.5.4 Cook Group Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.5.5 Cook Group Recent Development
11.6 Hikma Pharmaceuticals
11.6.1 Hikma Pharmaceuticals Company Details
11.6.2 Hikma Pharmaceuticals Business Overview
11.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Introduction
11.6.4 Hikma Pharmaceuticals Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.6.5 Hikma Pharmaceuticals Recent Development
11.7 Nippon Kayaku
11.7.1 Nippon Kayaku Company Details
11.7.2 Nippon Kayaku Business Overview
11.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Introduction
11.7.4 Nippon Kayaku Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.7.5 Nippon Kayaku Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Transarterial Chemoembolization (TACE) Introduction
11.8.4 Novartis AG Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Details
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Introduction
11.9.4 Pfizer Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.9.5 Pfizer Inc. Recent Development
11.10 Spectrum Pharmaceutical
11.10.1 Spectrum Pharmaceutical Company Details
11.10.2 Spectrum Pharmaceutical Business Overview
11.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Introduction
11.10.4 Spectrum Pharmaceutical Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.10.5 Spectrum Pharmaceutical Recent Development
11.11 Roche Holding AG
11.11.1 Roche Holding AG Company Details
11.11.2 Roche Holding AG Business Overview
11.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Introduction
11.11.4 Roche Holding AG Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.11.5 Roche Holding AG Recent Development
11.12 Celgene
11.12.1 Celgene Company Details
11.12.2 Celgene Business Overview
11.12.3 Celgene Transarterial Chemoembolization (TACE) Introduction
11.12.4 Celgene Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.12.5 Celgene Recent Development
11.13 Bayer AG
11.13.1 Bayer AG Company Details
11.13.2 Bayer AG Business Overview
11.13.3 Bayer AG Transarterial Chemoembolization (TACE) Introduction
11.13.4 Bayer AG Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.13.5 Bayer AG Recent Development
11.14 Merck & Co., Inc.
11.14.1 Merck & Co., Inc. Company Details
11.14.2 Merck & Co., Inc. Business Overview
11.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Introduction
11.14.4 Merck & Co., Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.14.5 Merck & Co., Inc. Recent Development
11.15 SingHealth
11.15.1 SingHealth Company Details
11.15.2 SingHealth Business Overview
11.15.3 SingHealth Transarterial Chemoembolization (TACE) Introduction
11.15.4 SingHealth Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025)
11.15.5 SingHealth Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis
Pfizer Inc
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer
Merck& Co. Inc
SingHealth
List of Tables
 Table 1. Global Transarterial Chemoembolization (TACE) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Chemotherapeutic Agents
 Table 3. Key Players of Radio Therapeutic Agents
 Table 4. Key Players of Drug-eluting Particles
 Table 5. Key Players of Others
 Table 6. Global Transarterial Chemoembolization (TACE) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Transarterial Chemoembolization (TACE) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Transarterial Chemoembolization (TACE) Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Transarterial Chemoembolization (TACE) Market Share by Region (2020-2025)
 Table 10. Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Transarterial Chemoembolization (TACE) Market Share by Region (2026-2031)
 Table 12. Transarterial Chemoembolization (TACE) Market Trends
 Table 13. Transarterial Chemoembolization (TACE) Market Drivers
 Table 14. Transarterial Chemoembolization (TACE) Market Challenges
 Table 15. Transarterial Chemoembolization (TACE) Market Restraints
 Table 16. Global Transarterial Chemoembolization (TACE) Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Transarterial Chemoembolization (TACE) Market Share by Players (2020-2025)
 Table 18. Global Top Transarterial Chemoembolization (TACE) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transarterial Chemoembolization (TACE) as of 2024)
 Table 19. Ranking of Global Top Transarterial Chemoembolization (TACE) Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Transarterial Chemoembolization (TACE) Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Transarterial Chemoembolization (TACE), Headquarters and Area Served
 Table 22. Global Key Players of Transarterial Chemoembolization (TACE), Product and Application
 Table 23. Global Key Players of Transarterial Chemoembolization (TACE), Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Transarterial Chemoembolization (TACE) Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Transarterial Chemoembolization (TACE) Revenue Market Share by Type (2020-2025)
 Table 27. Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Transarterial Chemoembolization (TACE) Revenue Market Share by Type (2026-2031)
 Table 29. Global Transarterial Chemoembolization (TACE) Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Transarterial Chemoembolization (TACE) Revenue Market Share by Application (2020-2025)
 Table 31. Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Transarterial Chemoembolization (TACE) Revenue Market Share by Application (2026-2031)
 Table 33. North America Transarterial Chemoembolization (TACE) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Transarterial Chemoembolization (TACE) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Transarterial Chemoembolization (TACE) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Transarterial Chemoembolization (TACE) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Transarterial Chemoembolization (TACE) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Questex Company Details
 Table 49. Questex Business Overview
 Table 50. Questex Transarterial Chemoembolization (TACE) Product
 Table 51. Questex Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 52. Questex Recent Development
 Table 53. Siemens Healthcare GmbH Company Details
 Table 54. Siemens Healthcare GmbH Business Overview
 Table 55. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Product
 Table 56. Siemens Healthcare GmbH Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 57. Siemens Healthcare GmbH Recent Development
 Table 58. Bellicum Pharmaceuticals Inc. Company Details
 Table 59. Bellicum Pharmaceuticals Inc. Business Overview
 Table 60. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Product
 Table 61. Bellicum Pharmaceuticals Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 62. Bellicum Pharmaceuticals Inc. Recent Development
 Table 63. Boston Scientific Company Details
 Table 64. Boston Scientific Business Overview
 Table 65. Boston Scientific Transarterial Chemoembolization (TACE) Product
 Table 66. Boston Scientific Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 67. Boston Scientific Recent Development
 Table 68. Cook Group Company Details
 Table 69. Cook Group Business Overview
 Table 70. Cook Group Transarterial Chemoembolization (TACE) Product
 Table 71. Cook Group Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 72. Cook Group Recent Development
 Table 73. Hikma Pharmaceuticals Company Details
 Table 74. Hikma Pharmaceuticals Business Overview
 Table 75. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Product
 Table 76. Hikma Pharmaceuticals Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 77. Hikma Pharmaceuticals Recent Development
 Table 78. Nippon Kayaku Company Details
 Table 79. Nippon Kayaku Business Overview
 Table 80. Nippon Kayaku Transarterial Chemoembolization (TACE) Product
 Table 81. Nippon Kayaku Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 82. Nippon Kayaku Recent Development
 Table 83. Novartis AG Company Details
 Table 84. Novartis AG Business Overview
 Table 85. Novartis AG Transarterial Chemoembolization (TACE) Product
 Table 86. Novartis AG Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 87. Novartis AG Recent Development
 Table 88. Pfizer Inc. Company Details
 Table 89. Pfizer Inc. Business Overview
 Table 90. Pfizer Inc. Transarterial Chemoembolization (TACE) Product
 Table 91. Pfizer Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 92. Pfizer Inc. Recent Development
 Table 93. Spectrum Pharmaceutical Company Details
 Table 94. Spectrum Pharmaceutical Business Overview
 Table 95. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Product
 Table 96. Spectrum Pharmaceutical Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 97. Spectrum Pharmaceutical Recent Development
 Table 98. Roche Holding AG Company Details
 Table 99. Roche Holding AG Business Overview
 Table 100. Roche Holding AG Transarterial Chemoembolization (TACE) Product
 Table 101. Roche Holding AG Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 102. Roche Holding AG Recent Development
 Table 103. Celgene Company Details
 Table 104. Celgene Business Overview
 Table 105. Celgene Transarterial Chemoembolization (TACE) Product
 Table 106. Celgene Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 107. Celgene Recent Development
 Table 108. Bayer AG Company Details
 Table 109. Bayer AG Business Overview
 Table 110. Bayer AG Transarterial Chemoembolization (TACE) Product
 Table 111. Bayer AG Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 112. Bayer AG Recent Development
 Table 113. Merck & Co., Inc. Company Details
 Table 114. Merck & Co., Inc. Business Overview
 Table 115. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Product
 Table 116. Merck & Co., Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 117. Merck & Co., Inc. Recent Development
 Table 118. SingHealth Company Details
 Table 119. SingHealth Business Overview
 Table 120. SingHealth Transarterial Chemoembolization (TACE) Product
 Table 121. SingHealth Revenue in Transarterial Chemoembolization (TACE) Business (2020-2025) & (US$ Million)
 Table 122. SingHealth Recent Development
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Transarterial Chemoembolization (TACE) Picture
 Figure 2. Global Transarterial Chemoembolization (TACE) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Transarterial Chemoembolization (TACE) Market Share by Type: 2024 VS 2031
 Figure 4. Chemotherapeutic Agents Features
 Figure 5. Radio Therapeutic Agents Features
 Figure 6. Drug-eluting Particles Features
 Figure 7. Others Features
 Figure 8. Global Transarterial Chemoembolization (TACE) Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Transarterial Chemoembolization (TACE) Market Share by Application: 2024 VS 2031
 Figure 10. Hospitals Case Studies
 Figure 11. Clinics Case Studies
 Figure 12. Cancer Research Centers Case Studies
 Figure 13. Transarterial Chemoembolization (TACE) Report Years Considered
 Figure 14. Global Transarterial Chemoembolization (TACE) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Transarterial Chemoembolization (TACE) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Transarterial Chemoembolization (TACE) Market Share by Region: 2024 VS 2031
 Figure 17. Global Transarterial Chemoembolization (TACE) Market Share by Players in 2024
 Figure 18. Global Top Transarterial Chemoembolization (TACE) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transarterial Chemoembolization (TACE) as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Transarterial Chemoembolization (TACE) Revenue in 2024
 Figure 20. North America Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Transarterial Chemoembolization (TACE) Market Share by Country (2020-2031)
 Figure 22. United States Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Transarterial Chemoembolization (TACE) Market Share by Country (2020-2031)
 Figure 26. Germany Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Transarterial Chemoembolization (TACE) Market Share by Region (2020-2031)
 Figure 34. China Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Transarterial Chemoembolization (TACE) Market Share by Country (2020-2031)
 Figure 42. Mexico Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Transarterial Chemoembolization (TACE) Market Share by Country (2020-2031)
 Figure 46. Turkey Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Transarterial Chemoembolization (TACE) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Questex Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 50. Siemens Healthcare GmbH Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 51. Bellicum Pharmaceuticals Inc. Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 52. Boston Scientific Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 53. Cook Group Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 54. Hikma Pharmaceuticals Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 55. Nippon Kayaku Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 56. Novartis AG Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 57. Pfizer Inc. Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 58. Spectrum Pharmaceutical Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 59. Roche Holding AG Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 60. Celgene Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 61. Bayer AG Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 62. Merck & Co., Inc. Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 63. SingHealth Revenue Growth Rate in Transarterial Chemoembolization (TACE) Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global TACE Embolic Microspheres Market Research Report 2024
Global Drug eluting Microsphere Market Research Report 2025
Global Drug Loadable Embolic Microspheres Market Research Report 2024
Global Lung Tumor Embolization Market Research Report 2025
Global Drug Eluting Beads Market Research Report 2024
Transcatheter Chemoembolization Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prostatic Arterial Embolization PAE Market Insights Forecast to 2030
Global Vascular Interventional Balloon Dilatation Catheters Market Research Report 2024
Interventional Oncology Ablation Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Radioembolization Microsphere Market Research Report 2024
Global Embolization Microsphere Market Insights Forecast to 2030
Global Embolization Particle Market Insights Forecast to 2030
Oncology Ablation Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Interventional Oncology Ablation Market Research Report 2024
Embolization Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hyperthermic Intraperitoneal Chemotherapy Equipment Market Research Report 2024
Global Chemotherapy Inject Medicine Pump Market Research Report 2024
Tumor Ablation and Interventional Radiology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
PVA Embolization Particles Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Transcathetar Devices Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions